BeiGene is a globally focused biopharma company focused on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer.
BeiGene Expands Global Pivotal Program for BTK Inhibitor BGB-3111 Mon, 13 Nov 2017 21:05:00 +0000 Initiates global Phase 3 trial of BGB-3111 compared to bendamustine and rituximab in treatment-naïve chronic lymphocytic leukemia/ small lymphocytic lymphoma patients Initiates global pivotal Phase 2 trial ...
BeiGene Reports Third Quarter 2017 Financial Results Mon, 13 Nov 2017 21:05:00 +0000 CAMBRIDGE, Mass. and BEIJING, China, Nov. 13, 2017-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology ...
China biotech's 'coming out party' masks long road ahead Thu, 19 Oct 2017 06:03:58 +0000 LONDON/SHANGHAI (Reuters) - Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West. Shares in firms such as Chi-Med (HCM.L), Beigene (BGNE.O) and Zai Lab (ZLAB.O) have soared on international markets this year, fuelled by hopes for their drugs and recent reforms to China's regulatory system that should speed up approvals. "It's almost a coming out party for China biotech," said Christian Hogg, chief executive of Hutchison China MediTech or Chi-Med, which presented promising data at a global medical congress this week on a lung cancer drug it discovered in China and is developing with AstraZeneca (AZN.L).
[$$] Celgene Invests in Acceleron, BeiGene Fri, 29 Sep 2017 09:50:00 +0000 Celgene doesn’t let a partner down. The biotech on Monday bought 750,000 more shares of Acceleron (XLRN) for $28 million in a public stock offering. Celgene (CELG) remains Acceleron’s largest holder and is a partner for the latter’s lead program, Luspatercept, and for sotatercept.
[$$] Celgene Launch to Lift BeiGene Tue, 12 Sep 2017 17:34:00 +0000 BeiGene (BGNE: Nasdaq) By Maxim Group ($72.64, Sept. 8, 2017) We have updated our BeiGene model to include the launch of BGB-A317 in the U.S. by Celgene, following the close of the transaction. Our model ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.